• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Murphy Canyon Acquisition Corp.

    9/29/23 4:30:08 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURF alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Amendment No. )*

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    CONDUIT PHARMACEUTICALS INC.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    20678X106

    (CUSIP Number)

     

    St George Street Capital

    Bates Wells Braithwaite

    10 Queen Street Place

    London, United Kingdom EC4R 1BE

    Attn: David Tapolczay, Trustee

    +44 (0) 7768 335460

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 22, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d - 1(b)

    ☒ Rule 13d - 1(c)

    ☐ Rule 13d - 1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 20678X106  

     

    1

    NAME OF REPORTING PERSON

    St George Street Capital

     

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

     

    3

    SEC USE ONLY

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    England and Wales

     

     

    NUMBER OF SHARES BENEFICIALLY

    OWNED BY EACH REPORTING PERSON WITH

    5

    SOLE VOTING POWER

     

    4,749,816 (1)
    6

    SHARED VOTING POWER

     

    0
    7

    SOLE DISPOSITIVE POWER

     

    4,749,816 (1)
    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY REPORTING PERSON

    4,749,816 (1)

     

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.6%

     

     
    12

    TYPE OF REPORTING PERSON

    OO (Charitable foundation)

     

     

     

    (1)Reflects shares of the common stock, $0.0001 par value per share, of Conduit Pharmaceuticals Inc. (formerly known as Murphy Canyon Acquisition Corp., the “Issuer”) received by St George Street Capital as consideration for the ordinary shares of Conduit Pharmaceuticals Limited that were previously held by St George Street Capital pursuant to the terms of the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023, by and among the Issuer, Conduit Pharmaceuticals Limited and Conduit Merger Sub, Inc.

     

     
     

     

    SCHEDULE 13G

     

    Item 1(a).

    Name of Issuer:

       
      Conduit Pharmaceuticals Inc. (formerly known as Murphy Canyon Acquisition Corp.) (the “Issuer”)
       
    Item 1(b). Address of Issuer’s Principal Executive Offices (as reported by the Issuer):
       
     

    4995 Murphy Canyon Road, Suite 300

    San Diego, California

       
    Item 2(a).

    Name of Person Filing:

       
      This Statement on Schedule 13G (this “Statement”) is filed by St George Street Capital. The foregoing entity is sometimes referred to herein as the “Reporting Person.”
       
    Item 2(b). Address of Principal Business Office or, if none, Residence:
       
      The business address of the Reporting Person is Bates Wells Braithwaite, 10 Queen Street Place, London, United Kingdom EC4R 1BE.
       
    Item 2(c).

    Citizenship:

       
      The Reporting Person is charitable foundation organized under the laws of England and Wales
       
    Item 2(d).

    Title of Class of Securities:

       
      Common Stock, $0.0001 par value per share (“Common Stock”)
       
    Item 2(e).

    CUSIP Number:

       
      20678X106
       
    Item 3. If this statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act;
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act;
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
           
          Not applicable

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ________________________

     

    Not applicable

     

     
     

     

    Item 4. Ownership:

     

      (a) Amount beneficially owned: 4,749,816
         
      (b) Percent of class: 6.6%
         
      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote: 4,749,816
         
      (ii) Shared power to vote or to direct the vote: 0
         
      (iii) Sole power to dispose or to direct the disposition of: 4,749,816
         
      (iv)

    Shared power to dispose or to direct the disposition of: 0

     

    The Issuer’s Chief Executive Officer, David Tapolczay, is also a trustee of the Reporting Person. However, Mr. Tapolczay does not have or control the voting or dispositive power of the shares of Common Stock referred to herein as being held by the Reporting Person.

     

    Item 5. Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable.
       
    Item 8. Identification and Classification of Members of the Group: Not Applicable.
       
    Item 9. Notice of Dissolution of Group: Not Applicable.
       
    Item 10. Certifications:
       
      By signing below each of the Reporting Persons certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.


     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

     

    Dated: September 29, 2023

     

    ST GEORGE STREET CAPITAL  
         
    By: /s/ David Tapolczay  
    Name:  David Tapolczay  
    Title: Trustee  

     

     

     

    Get the next $MURF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MURF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lewis-Hall Freda C

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/14/23 5:16:03 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mcnealey Jennifer Isacoff

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:25 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bligh James

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:29 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives

    SAN DIEGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ:SQFT, SQFTP))) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors (the "Board") has established a Special Committee of the Board (the "Special Committee") to explore potential strategic alternatives focusing on maximizing stockholder value. The Special Committee is comprised solely of independent directors and is charged with exploring potential strategic alternatives, including, without limitation, a business combination involving the Company, a sale of all or part of the Company's assets, joint venture arrangements and/or

    9/13/23 8:30:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    SEC Filings

    View All

    SEC Form S-8 filed by Murphy Canyon Acquisition Corp.

    S-8 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    1/10/24 4:43:04 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.

    424B3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 4:14:52 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.

    EFFECT - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 12:15:16 AM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Financials

    Live finance-specific insights

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended June 30, 2023

    SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Presidio Property Trust, Inc. (NASDAQ:SQFT)(NASDAQ:SQFTP) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today reported earnings for its quarter ended June 30, 2023.Quarter Ended June 30, 2023, Financial ResultsNet loss attributable to the Company's common stockholders for the three months ended June 30, 2023, was approximately $1,831,889, or $(0.15) per basic and diluted share, compared to a net loss of approximately $830,212, or $(0.07) per basic and diluted share for the three months ended June 30, 2022. The change in net income attributable to the Company's common stockholders was a result of: •An

    8/14/23 5:30:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/12/24 12:51:14 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/8/24 1:15:17 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/2/24 4:28:59 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care